Ryan Deschner
Stock Analyst at Raymond James
(4.76)
# 614
Out of 4,988 analysts
71
Total ratings
67.2%
Success rate
36.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Reiterated: Buy | n/a | $34.00 | - | 8 | Sep 15, 2026 | |
| LQDA Liquidia | Reiterated: Buy | $106 | $66.88 | +58.49% | 13 | Aug 13, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $27 → $40 | $14.95 | +167.56% | 6 | Aug 7, 2026 | |
| ACOG Alpha Cognition | Initiated Coverage: Buy | $20 | $8.84 | +126.24% | 1 | Jul 10, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $10 | $1.63 | +513.50% | 5 | Jul 8, 2026 | |
| ACHV Achieve Life Sciences | Initiated Coverage: Buy | $20 | $7.98 | +150.63% | 1 | Jun 26, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $14 → $10 | $1.83 | +446.45% | 2 | Jun 26, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | n/a | $28.99 | - | 2 | Jun 24, 2026 | |
| DNTH Dianthus Therapeutics | Reiterated: Buy | n/a | $96.81 | - | 5 | Jun 12, 2026 | |
| ADMA ADMA Biologics | Initiated Coverage: Buy | $21 | $9.11 | +130.52% | 1 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $2.09 | +330.62% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $110 → $165 | $91.83 | +79.68% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $23 | $10.02 | +129.54% | 2 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.11 | - | 11 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $54 → $143 | $150.56 | -5.02% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $12 | $3.42 | n/a | 4 | Aug 5, 2025 |
Vera Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $34.00
Upside: -
Liquidia
Aug 13, 2026
Reiterated: Buy
Price Target: $106
Current: $66.88
Upside: +58.49%
Trevi Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $27 → $40
Current: $14.95
Upside: +167.56%
Alpha Cognition
Jul 10, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $8.84
Upside: +126.24%
Tvardi Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $10
Current: $1.63
Upside: +513.50%
Achieve Life Sciences
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.98
Upside: +150.63%
ProQR Therapeutics
Jun 26, 2026
Reiterated: Buy
Price Target: $14 → $10
Current: $1.83
Upside: +446.45%
Viking Therapeutics
Jun 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $28.99
Upside: -
Dianthus Therapeutics
Jun 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $96.81
Upside: -
ADMA Biologics
Jun 10, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $9.11
Upside: +130.52%
May 13, 2026
Reiterated: Buy
Price Target: $9
Current: $2.09
Upside: +330.62%
May 7, 2026
Reiterated: Buy
Price Target: $110 → $165
Current: $91.83
Upside: +79.68%
Mar 13, 2026
Upgraded: Buy
Price Target: $23
Current: $10.02
Upside: +129.54%
Jan 9, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.11
Upside: -
Nov 19, 2025
Upgraded: Buy
Price Target: $54 → $143
Current: $150.56
Upside: -5.02%
Aug 5, 2025
Reiterated: Buy
Price Target: $11 → $12
Current: $3.42
Upside: n/a